

EXPLANATION OF HOW KEY ELEMENTS OF THE BENCHMARK METHODOLOGY REFLECT ENVIRONMENTAL, SOCIAL, AND GOVERNANCE (ESG) FACTORS

Solactive Pharma Breakthrough Value Index



This document provides an explanation of how the key elements of the benchmark methodology reflect ESG factors. It is compiled in accordance with the requirements of point (d) of Article 13 (1) of Regulation (EU) 2016/1011 of the European Parliament and of the Council of 8 June 2016 (the "Benchmarks Regulation") and of the Commission Delegated Regulation (EU) 2020/1817.

General Information

Name of the benchmark administrator	Solactive AG
Type of benchmark or family of benchmarks	Equity
Name of the benchmark or family of benchmarks	Solactive Pharma Breakthrough Value Index (DE000SLA30N4)
Does the benchmark methodology for the benchmark or family of benchmarks take into account ESG factors?	Yes

ESG Factors Applied in the Benchmark Methodology

List of environmental factors considered	<ul style="list-style-type: none">> Compliance with UNGC norms around environment, human rights, corruption and labour rights.> Not breaching any severe ESG controversies.> Deriving less than 5% of revenues from the production or distribution of nuclear power or supporting products or power generation capacity increase.> Deriving less than 5% of revenues from thermal coal extraction, power generation or supporting products/services or power generation capacity increase.> Deriving less than 5% of revenues from conventional oil & gas generation, production and supporting products service or power generation capacity increase.> Deriving less than 5% of revenues from oil sands extraction, Arctic oil & gas exploration/extraction or shale energy extraction or power generation capacity increase.
List of social factors considered	<ul style="list-style-type: none">> The index selects stocks of companies that are actively engaged in the research, development and/or manufacturing of orphan drugs. An "orphan drug" is a pharmaceutical product that has been developed specifically to treat rare diseases or disorders. The assignment of "orphan" status to any drugs developed to treat a rare disease is a matter of public policy in many countries and has resulted in medical breakthroughs that may not have otherwise been achieved due to the economics of drug research and development> Compliance with UNGC norms around environment, human rights, corruption and labour rights.> Not breaching any severe ESG controversies.> Deriving less than 5% of revenues from tobacco production, distribution and related services.



	<ul style="list-style-type: none">> Deriving less than 5% of revenues from military contracting weapons and related products.> Having no direct or indirect involvement through corporate ownership of controversial weapons companies.> Deriving less than 5% of revenues from assault and non-assault weapons (including civilian customers, key components, military/law enforcement customers, and retail/distribution).> Deriving less than 5% of revenues from gambling operations, specialized equipment or supporting products/services.> Deriving less than 5% of revenues from adult entertainment production or distribution.> Deriving less than 5% of revenues from alcohol production, distribution or related services.
List of governance factors considered	<ul style="list-style-type: none">> Compliance with UNGC norms around environment, human rights, corruption and labour rights.> Not breaching any severe ESG controversies.

Data and Standards used

Data Input	The data used to construct the index is sourced externally from EvaluatePharma and Sustainalytics.
Verification and quality of data	The provider of ESG-related data input is selected by the Administrator based on an assessment of its existing processes in order to ensure the reliability and representativeness of the ESG-related data. The data provider has established processes in accordance with accepted and established market standards that ensure the permanent quality and reliability of the ESG-data provided.
Reference standards	International standards referenced by the index methodology are listed in the respective section above.
Information updated on	19/12/2025
Reason for update:	Initial document creation

CONTACT

Solactive AG
German Index Engineering

Platz der Einheit 1
60327 Frankfurt am Main
Germany

Tel.: +49 (0) 69 719 160 00
Fax: +49 (0) 69 719 160 25
Email: info@solactive.com
Website: www.solactive.com

© Solactive AG